Wu Xia, Zou Shengyu, Wu Fan, He Zuhong, Kong Weijia
Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430022, P. R. China.
Otorhinolaryngology Department, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University 107 West Yan Jiang Road, Guangzhou 510120, P. R. China.
Am J Stem Cells. 2020 Apr 25;9(2):16-24. eCollection 2020.
Deafness is one of the major global health problems that seriously affects the quality of human life. At present, there are no successful treatments for deafness caused by cochlear hair cell (HC) damage. The irreversibility of mammalian hearing impairment is that the inner ear's sensory epithelium cannot repair lost hair cells and neurons through spontaneous regeneration. The goal of stem cell therapy for sensorineural hearing loss is to reconstruct the damaged inner ear structure and achieve functional repair. microRNA (miRNA), as a class of highly conserved endogenous non-coding small RNAs, plays an important role in the development of cochlea and HCs. miRNA also participates in the regulation of stem cell proliferation and differentiation, and plays an important role in the process of regeneration of inner ear HCs, miRNA has a broad application prospect of clinical treatment of hearing loss, which is conducive to solving the medical problem of inner ear HC regeneration.
耳聋是严重影响人类生活质量的主要全球健康问题之一。目前,对于由耳蜗毛细胞(HC)损伤引起的耳聋尚无成功的治疗方法。哺乳动物听力损伤的不可逆性在于内耳的感觉上皮不能通过自发再生修复丢失的毛细胞和神经元。干细胞治疗感音神经性听力损失的目标是重建受损的内耳结构并实现功能修复。微小RNA(miRNA)作为一类高度保守的内源性非编码小RNA,在耳蜗和毛细胞的发育中起重要作用。miRNA还参与干细胞增殖和分化的调节,并在内耳毛细胞再生过程中起重要作用,miRNA在听力损失的临床治疗中具有广阔的应用前景,有利于解决内耳毛细胞再生的医学问题。